504 completed, 146 terminated, 144 active not recruiting, 125 recruiting. 682 Phase 2, 370 Phase 1, 175 Phase 3, 20 Phase 4, 14 Not applicable.
Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Phase 1 | Not yet recruiting | City of Hope Medical Center | 14 | 2027-05-16 | 2026-11-09 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-11-18 |
| To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 750 | 2027-02-01 | 2026-11-16 |
| Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Not yet recruiting | Istituto Oncologico Veneto IRCCS | 14 | 2027-01-31 | 2026-11-03 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 25 | 2027-01-01 | 2026-11-03 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Ramantamig, Daratumumab, Bortezomib - Multiple Myeloma | Phase 3 | Not yet recruiting | Janssen Research & Development, LLC | 1000 | 2026-12-14 | 2026-11-04 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 55 | 2026-12-01 | 2026-09-10 |
| Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma | Phase 3 | Recruiting | PrECOG, LLC. | 500 | 2026-12-01 | 2026-11-12 |
| Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 29 | 2026-12-01 | 2026-11-16 |
| Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma Lenalidomide, Bruton's tyrosine kinase inhibitor, Chidamide - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 87 | 2026-11-01 | 2026-11-04 |
| CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-10-15 | 2026-10-26 |
| F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma F182112 Plus Isatuximab and Lenalidomide - Multiple Myeloma (MM), Transplant-eligible Patients | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-10-01 | 2026-09-18 |
| Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL Zanubrutinib, Lenalidomide - Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib | Phase 2 | Recruiting | Xiaohui Ren | 33 | 2026-09-25 | 2026-11-10 |
| A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). AZD0120, Cyclophosphamide, Fludarabine - Newly Diagnosed Multiple Myeloma (NDMM) | Phase 3 | Recruiting | AstraZeneca | 750 | 2026-09-24 | 2026-10-21 |
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-09-15 | 2026-09-18 |
| A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned Ramantamig, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1000 | 2026-09-09 | 2026-11-03 |
Showing 20 of 1111. Sign in to see all of them.
Multiple Myeloma (444) · Lymphoma, Large B-Cell, Diffuse (102) · Leukemia, Lymphocytic, Chronic, B-Cell (89) · Lymphoma, Follicular (82) · Recurrence (79) · Lymphoma (62) · Lymphoma, Mantle-Cell (60) · Neoplasms, Plasma Cell (59) · Myelodysplastic Syndromes (52) · Lymphoma, B-Cell, Marginal Zone (47) · Lymphoma, Non-Hodgkin (47) · Leukemia, Myeloid, Acute (34) · Leukemia (32) · Lymphoma, B-Cell (24) · Neoplasms (24)
Celgene (63) · M.D. Anderson Cancer Center (60) · National Cancer Institute (NCI) (57) · Mayo Clinic (29) · Celgene Corporation (23) · Memorial Sloan Kettering Cancer Center (22) · Ruijin Hospital (21) · Janssen Research & Development, LLC (20) · Bristol-Myers Squibb (15) · Dana-Farber Cancer Institute (14) · H. Lee Moffitt Cancer Center and Research Institute (13) · The First Affiliated Hospital with Nanjing Medical University (13) · Massachusetts General Hospital (12) · PETHEMA Foundation (12) · The Lymphoma Academic Research Organisation (12)
United States (640) · China (155) · France (149) · Spain (128) · Germany (122) · Italy (115) · United Kingdom (94) · Canada (85) · Australia (80) · Belgium (73) · Japan (57) · Poland (57) · South Korea (57) · Austria (56) · Czechia (54)
Robert Knight, MD (11) · Ravi Vij, M.D. (5) · Shaji K. Kumar, MD (5) · Hani Hassoun, MD (4) · James R Berenson, MD (4) · Paul Richardson, MD (4)
PMID 29358183, PMID 33357481, PMID 39319495, PMID 23834234, PMID 35285981, PMID 35985959, PMID 31221778, PMID 35549810, PMID 38062124, PMID 18799726, PMID 18824593, PMID 19901114, PMID 21273172, PMID 23194056, PMID 26181891, PMID 27531679, PMID 27705267, PMID 28314699, PMID 28379796, PMID 28651604, PMID 28803351, PMID 30561775, PMID 32325490, PMID 34182226, PMID 34289038, PMID 34549906, PMID 34587246, PMID 34780623, PMID 34826409, PMID 35132679, PMID 35660812, PMID 35787017, PMID 35952327, PMID 36882409, PMID 37369099, PMID 37990162, PMID 38023148, PMID 38031761, PMID 38048552, PMID 38084760, PMID 38649340, PMID 38652812, PMID 39229471, PMID 39293025, PMID 39321347, PMID 39374535, PMID 40802906, PMID 41915772, PMID 17021321, PMID 17893227
2023 (34), 2009 (17), P30CA015083 (16), U10CA180820 (11), U10CA180821 (9), 2015 (8), 2019 (8), U10CA021115 (8), U10CA031946 (8), 2008 (7), 2025 (7), P30CA016058 (7), U01CA076576 (7), U10CA180888 (7), U10CA032102 (6)